Inhibition of human metapneumovirus binding to heparan sulfate blocks infection in human lung cells and airway tissues

Journal of Virology

Volumn 90, Issue 20, 2016, Pages 9237-9250

  Klimyte, Edita M ^a   Smith, Stacy E ^a   Oreste, Pasqua ^b   Lembo, David ^c   Dutch, Rebecca Ellis ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Glycores 2000 Srl   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; HEPARAN SULFATE; VIRUS FUSION PROTEIN; ANTIVIRUS AGENT; CAPSULAR POLYSACCHARIDE K5; DENDRIMER; PEPTIDE; PROTEOHEPARAN SULFATE; SB105-A10;

ANTIVIRAL ACTIVITY; ARTICLE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN METAPNEUMOVIRUS; HUMAN METAPNEUMOVIRUS INFECTION; HUMAN TISSUE; INFECTION PREVENTION; LUNG ALVEOLUS CELL; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN FUNCTION; SULFATION; VIRUS ATTACHMENT; A-549 CELL LINE; BACTERIAL CAPSULE; CELL LINE; DRUG EFFECTS; ESCHERICHIA COLI; METABOLISM; METAPNEUMOVIRUS; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY SYSTEM; TUMOR CELL LINE; VIROLOGY;

A549 CELLS; ANTIVIRAL AGENTS; BACTERIAL CAPSULES; CELL LINE; CELL LINE, TUMOR; DENDRIMERS; ESCHERICHIA COLI; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HUMANS; METAPNEUMOVIRUS; PARAMYXOVIRIDAE INFECTIONS; PEPTIDES; RESPIRATORY SYSTEM; VIRAL FUSION PROTEINS;

EID: 84990061873     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01362-16     Document Type: Article

References (74)

1. Monto AS. 2002. Epidemiology of viral respiratory infections. Am J Med 112(Suppl 6A):4S-12S.
2. van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, Osterhaus AD. 2001. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 7:719-724. http://dx.doi.org/10.1038/89098.
3. van den Hoogen BG, van Doornum GJ, Fockens JC, Cornelissen JJ, Beyer WE, de Groot R, Osterhaus AD, Fouchier RA. 2003. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J Infect Dis 188:1571-1577. http://dx.doi.org/10.1086/379200.
4. van den Hoogen BG, Osterhaus DM, Fouchier RA. 2004. Clinical impact and diagnosis of human metapneumovirus infection. Pediatr Infect Dis J 23:S25-S32. http://dx.doi.org/10.1097/01.inf.0000108190.09824.e8.
5. Don M, Korppi M, Valent F, Vainionpaa R, Canciani M. 2008. Human metapneumovirus pneumonia in children: results of an Italian study and mini-review. Scand J Infect Dis 40:821-826. http://dx.doi.org/10.1080/00365540802227110.
6. Kahn JS. 2006. Epidemiology of human metapneumovirus. Clin Microbiol Rev 19:546-557. http://dx.doi.org/10.1128/CMR.00014-06.
7. Deffrasnes C, Hamelin ME, Boivin G. 2007. Human metapneumovirus. Semin Respir Crit Care Med 28:213-221. http://dx.doi.org/10.1055/s-2007-976493.
8. Boivin G, De Serres G, Cote S, Gilca R, Abed Y, Rochette L, Bergeron MG, Dery P. 2003. Human metapneumovirus infections in hospitalized children. Emerg Infect Dis 9:634-640. http://dx.doi.org/10.3201/eid0906.030017.
9. Esper F, Boucher D, Weibel C, Martinello RA, Kahn JS. 2003. Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children. Pediatrics 111:1407-1410. http://dx.doi.org/10.1542/peds.111.6.1407.
10. Esper F, Martinello RA, Boucher D, Weibel C, Ferguson D, Landry ML, Kahn JS. 2004. A 1-year experience with human metapneumovirus in children aged <5 years. J Infect Dis 189:1388-1396. http://dx.doi.org/10.1086/382482.
11. Feuillet F, Lina B, Rosa-Calatrava M, Boivin G. 2012. Ten years of human metapneumovirus research. J Clin Virol 53:97-105. http://dx.doi.org/10.1016/j.jcv.2011.10.002.
12. Schildgen O, Glatzel T, Geikowski T, Scheibner B, Matz B, Bindl L, Born M, Viazov S, Wilkesmann A, Knopfle G, Roggendorf M, Simon A. 2005 Human metapneumovirus RNA in encephalitis patient. Emerg Infect Dis 11:467-470. http://dx.doi.org/10.3201/eid1103.040676.
13. Arnold JC, Singh KK, Milder E, Spector SA, Sawyer MH, Gavali S, Glaser C. 2009. Human metapneumovirus associated with central nervous system infection in children. Pediatr Infect Dis J 28:1057-1060. http://dx.doi.org/10.1097/INF.0b013e3181acd221.
14. Niizuma T, Okumura A, Kinoshita K, Shimizu T. 2014. Acute encephalopathy associated with human metapneumovirus infection. Jpn J Infect Dis 67:213-215. http://dx.doi.org/10.7883/yoken.67.213.
15. Weinreich, MA, Jabbar AY, Malguria N, Haley RW. 2015. New-onset myocarditis in an immunocompetent adult with acute metapneumovirus infection. Case Rep Med 2015:814269.
16. Principi N, Esposito S. 2014. Paediatric human metapneumovirus infection: epidemiology, prevention, and therapy. J Clin Virol 59:141-147. http://dx.doi.org/10.1016/j.jcv.2014.01.003.
17. Chang A, Masante C, Buchholz UJ, Dutch RE. 2012. Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate. J Virol 86:3230-3243 http://dx.doi.org/10.1128/JVI.06706-11.
18. Cox RG, Mainou BA, Johnson M, Hastings AK, Schuster JE, Dermody TS, Williams JV. 2015. Human metapneumovirus is capable of entering cells by fusion with endosomal membranes. PLoS Pathog 11:e1005303. http://dx.doi.org/10.1371/journal.ppat.1005303.
19. Cseke G, Maginnis MS, Cox RG, Tollefson SJ, Podsiad AB, Wright DW, Dermody TS, Williams JV. 2009. Integrin αvβ1 promotes infection by human metapneumovirus. Proc Natl Acad SciUSA106:1566-1571. http://dx.doi.org/10.1073/pnas.0801433106.
20. Cox RG, Livesay SB, Johnson M, Ohi MD, Williams JV. 2012. The human metapneumovirus fusion protein mediates entry via an interaction with RGD-binding integrins. J Virol 86:12148-12160. http://dx.doi.org/10.1128/JVI.01133-12.
21. Feldman SA, Audet S, Beeler JA. 2000. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol 74:6442-6447. http://dx.doi.org/10.1128/JVI.74.14.6442-6447.2000.
22. Hallak LK, Collins PL, Knudson W, Peeples ME. 2000. Iduronic acidcontaining glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology 271:264-275. http://dx.doi.org/10.1006/viro.2000.0293.
23. Escribano-Romero E, Rawling J, Garcia-Barreno B, Melero JA. 2004. The soluble form of human respiratory syncytial virus attachment protein differs from the membrane-bound form in its oligomeric state but is still capable of binding to cell surface proteoglycans. J Virol 78:3524-3532. http://dx.doi.org/10.1128/JVI.78.7.3524-3532.2004.
24. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75: 1565-1570. http://dx.doi.org/10.1128/JVI.75.3.1565-1570.2001.
25. WuDunn D, Spear PG. 1989. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 63:52-58.
26. Shieh MT, WuDunn D, Montgomery RI, Esko JD, Spear PG. 1992. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol 116:1273-1281. http://dx.doi.org/10.1083/jcb.116.5.1273.
27. Herold BC, Visalli RJ, Susmarski N, Brandt CR, Spear PG. 1994. Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulfate and glycoprotein B J Gen Virol 75:1211-1222.
28. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosenberg RD, Spear PG. 1999. A novel role for 3-Osulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99:13-22. http://dx.doi.org/10.1016/S0092-8674(00)80058-6.
29. Patel M, Yanagishita M, Roderiquez G, Bou-Habib DC, Oravecz T, Hascall VC, Norcross MA. 1993. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res Hum Retroviruses 9:167-174. http://dx.doi.org/10.1089/aid.1993.9.167.
30. de Witte L, Bobardt M, Chatterji U, Degeest G, David G, Geijtenbeek TB, Gallay P. 2007. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci U S A 104:19464-19469. http://dx.doi.org/10.1073/pnas.0703747104.
31. Crublet E, Andrieu JP, Vives RR, Lortat-Jacob H. 2008. The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the coreceptor binding site. J Biol Chem 283:15193-15200 http://dx.doi.org/10.1074/jbc.M800066200.
32. Spillmann D. 2001. Heparan sulfate: anchor for viral intruders? Biochimie 83:811-817. http://dx.doi.org/10.1016/S0300-9084(01)01290-1.
33. Biacchesi S, Skiadopoulos MH, Yang L, Lamirande EW, Tran KC, Murphy BR, Collins PL, Buchholz UJ. 2004. Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol 78:12877-12887. http://dx.doi.org/10.1128/JVI.78.23.12877-12887.2004.
34. Biacchesi S, Pham QN, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. 2005. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J Virol 79:12608-12613. http://dx.doi.org/10.1128/JVI.79.19.12608-12613.2005.
35. Schowalter RM, Chang A, Robach JG, Buchholz UJ, Dutch RE. 2009. Low-pH triggering of human metapneumovirus fusion: essential residues and importance in entry. J Virol 83:1511-1522. http://dx.doi.org/10.1128/JVI.01381-08.
36. Sabo Y, Ehrlich M, Bacharach E. 2011. The conserved YAGL motif in human metapneumovirus is required for higher-order cellular assemblies of the matrix protein and for virion production. J Virol 85:6594-6609. http://dx.doi.org/10.1128/JVI.02694-10.
37. Schowalter RM, Smith SE, Dutch RE. 2006. Characterization of human metapneumovirus F protein-promoted membrane fusion: critical roles for proteolytic processing and low pH. J Virol 80:10931-10941. http://dx.doi.org/10.1128/JVI.01287-06.
38. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, Ribatti D, Rusnati M, Presta M. 2001. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 276:37900-37908.
39. Biacchesi S, Murphy BR, Collins PL, Buchholz UJ. 2007. Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro. J Virol 81:6057-6067. http://dx.doi.org/10.1128/JVI.00128-07.
40. Paterson RG, Lamb RA. 1993. The molecular biology of influenza viruses and paramyxoviruses, p 35-73. In Davidson A, ElliottRM(ed), Molecular virology: a practical approach. IRL Oxford University Press, Oxford, United Kingdom.
41. de Graaf M, Herfst S, Aarbiou J, Burgers PC, Zaaraoui-Boutahar F, Bijl M, van Ijcken W, Schrauwen EJ, Osterhaus AD, Luider TM, Scholte BJ, Fouchier RA, Andeweg AC. 2013. Small hydrophobic protein of human metapneumovirus does not affect virus replication and host gene expression in vitro. PLoS One 8:e58572. http://dx.doi.org/10.1371/journal.pone.0058572.
42. Ahmadi A, Zorofchian-Moghadamtousi S, Abubakar S, Zandi K. 2015. Antiviral potential of algae polysaccharides isolated from marine sources: a review. Biomed Res Int 2015:825203.
43. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT. 2006 Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2:e69. http://dx.doi.org/10.1371/journal.ppat.0020069.
44. Lynch G, Low L, Li S, Sloane A, Adams S, Parish C, Kemp B, Cunningham AL. 1994. Sulfated polyanions prevent HIV infection of lymphocytes by disruption of the CD4-gp120 interaction, but do not inhibit monocyte infection. J Leukoc Biol 56:266-272.
45. Talarico LB, Noseda MD, Ducatti DR, Duarte ME, Damonte EB. 2011. Differential inhibition of dengue virus infection in mammalian and mosquito cells by iota-carrageenan. J Gen Virol 92:1332-1342. http://dx.doi.org/10.1099/vir.0.028522-0.
46. Leibbrandt A, Meier C, Konig-Schuster M, Weinmullner R, Kalthoff D, Pflugfelder B, Graf P, Frank-Gehrke B, Beer M, Fazekas T, Unger H, Prieschl-Grassauer E, Grassauer A. 2010. Iota-carrageenan is a potent inhibitor of influenza A virus infection. PLoS One 5:e14320. http://dx.doi.org/10.1371/journal.pone.0014320.
47. Eccles R, Meier C, Jawad M, Weinmullner R, Grassauer A, Prieschl-Grassauer E. 2010. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res 11:108. http://dx.doi.org/10.1186/1465-9921-11-108.
48. Fazekas T, Eickhoff P, Pruckner N, Vollnhofer G, Fischmeister G, Diakos C, Rauch M, Verdianz M, Zoubek A, Gadner H, Lion T. 2012. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. BMC Comp Altern Med 12:147. http://dx.doi.org/10.1186/1472-6882-12-147.
49. Ludwig M, Enzenhofer E, Schneider S, Rauch M, Bodenteich A, Neumann K, Prieschl-Grassauer E, Grassauer A, Lion T, Mueller CA. 2013. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial. Respir Res 14:124. http://dx.doi.org/10.1186/1465-9921-14-124.
50. Hayashi K, Hayashi M, Jalkanen M, Firestone JH, Trelstad RL, Bernfield M. 1987. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues: a light and electron microscopic study. J Histochem Cytochem 35:1079-1088. http://dx.doi.org/10.1177/35.10.2957423.
51. Palmer SG, Porotto M, Palermo LM, Cunha LF, Greengard O, Moscona A. 2012. Adaptation of human parainfluenza virus to airway epithelium reveals fusion properties required for growth in host tissue. mBio 3:e00137-12. http://dx.doi.org/10.1128/mBio.00137-12.
52. Bai J, Smock SL, Jackson GR, Jr, MacIsaac KD, Huang Y, Mankus C, Oldach J, Roberts B, Ma YL, Klappenbach JA, Crackower MA, Alves SE, Hayden PJ. 2015. Phenotypic responses of differentiated asthmatic human airway epithelial cultures to rhinovirus. PLoS One 10:e0118286. http://dx.doi.org/10.1371/journal.pone.0118286.
53. Deng X, Li Y, Qiu J. 2014. Human bocavirus 1 infects commercially available primary human airway epithelium cultures productively. J Virol Methods 195:112-119. http://dx.doi.org/10.1016/j.jviromet.2013.10.012.
54. Donalisio M, Rusnati M, Cagno V, Civra A, Bugatti A, Giuliani A, Pirri G, Volante M, Papotti M, Landolfo S, Lembo D. 2012. Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide. Antimicrob Agents Chemother 56:5278-5288. http://dx.doi.org/10.1128/AAC.00771-12.
55. Cagno V, Donalisio M, Civra A, Volante M, Veccelli E, Oreste P, Rusnati M, Lembo D. 2014. Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures. Antimicrob Agents Chemother 58:4782-4794. http://dx.doi.org/10.1128/AAC.02594-14.
56. Vervaeke P, Alen M, Noppen S, Schols D, Oreste P, Liekens S. 2013. Sulfated Escherichia coli K5 polysaccharide derivatives inhibit dengue virus infection of human microvascular endothelial cells by interacting with the viral envelope protein E domain III. PLoS One 8:e74035. http://dx.doi.org/10.1371/journal.pone.0074035.
57. Mercorelli B, Oreste P, Sinigalia E, Muratore G, Lembo D, Palu G, Loregian A. 2010. Sulfated derivatives of Escherichia coli K5 capsular polysaccharide are potent inhibitors of human cytomegalovirus. Antimicrob Agents Chemother 54:4561-4567. http://dx.doi.org/10.1128/AAC.00721-10.
58. Pinna D, Oreste P, Coradin T, Kajaste-Rudnitski A, Ghezzi S, Zoppetti G, Rotola A, Argnani R, Poli G, Manservigi R, Vicenzi E. 2008. Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide. Antimicrob Agents Chemother 52:3078-3084. http://dx.doi.org/10.1128/AAC.00359-08.
59. Vicenzi E, Gatti A, Ghezzi S, Oreste P, Zoppetti G, Poli G. 2003. Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives. AIDS 17:177-181. http://dx.doi.org/10.1097/00002030-200301240-00006.
60. Esko JD, Selleck SB. 2002. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 71:435-471. http://dx.doi.org/10.1146/annurev.biochem.71.110601.135458.
61. Luganini A, Giuliani A, Pirri G, Pizzuto L, Landolfo S, Gribaudo G. 2010 Peptide-derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate. Antiviral Res 85:532-540. http://dx.doi.org/10.1016/j.antiviral.2010.01.003.
62. Bon I, Lembo D, Rusnati M, Clo A, Morini S, Miserocchi A, Bugatti A, Grigolon S, Musumeci G, Landolfo S, Re MC, Gibellini D. 2013. Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. PLoS One 8:e76482. http://dx.doi.org/10.1371/journal.pone.0076482.
63. Donalisio M, Rusnati M, Civra A, Bugatti A, Allemand D, Pirri G, Giuliani A, Landolfo S, Lembo D. 2010. Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses. Antimicrob Agents Chemother 54:4290-4299. http://dx.doi.org/10.1128/AAC.00471-10.
64. Luganini A, Nicoletto SF, Pizzuto L, Pirri G, Giuliani A, Landolfo S, Gribaudo G. 2011. Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers. Antimicrob Agents Chemother 55:3231-3239. http://dx.doi.org/10.1128/AAC.00149-11.
65. Salvador B, Sexton NR, Carrion R, Jr, Nunneley J, Patterson JL, Steffen I, Lu K, Muench MO, Lembo D, Simmons G. 2013. Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol 87:3295-3304 http://dx.doi.org/10.1128/JVI.01621-12.
66. Mendes GS, Duarte ME, Colodi FG, Noseda MD, Ferreira LG, Berte SD, Cavalcanti JF, Santos N, Romanos MT. 2014. Structure and antimetapneumovirus activity of sulfated galactans from the red seaweed Cryptonemia seminervis. Carbohydr Polymers 101:313-323. http://dx.doi.org/10.1016/j.carbpol.2013.09.026.
67. Grassauer A, Weinmuellner R, Meier C, Pretsch A, Prieschl-Grassauer E, Unger H. 2008. Iota-carrageenan is a potent inhibitor of rhinovirus infection. Virol J 5:107. http://dx.doi.org/10.1186/1743-422X-5-107.
68. Hallak LK, Spillmann D, Collins PL, Peeples ME. 2000. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 74:10508-10513. http://dx.doi.org/10.1128/JVI.74.22.10508-10513.2000.
69. Masante C, El Najjar F, Chang A, Jones A, Moncman CL, Dutch RE. 2014 The human metapneumovirus small hydrophobic protein has properties consistent with those of a viroporin and can modulate viral fusogenic activity. J Virol 88:6423-6433. http://dx.doi.org/10.1128/JVI.02848-13.
70. Le Nouen C, Hillyer P, Brock LG, Winter CC, Rabin RL, Collins PL, Buchholz UJ. 2014. Human metapneumovirus SH and G glycoproteins inhibit macropinocytosis-mediated entry into human dendritic cells and reduce CD4 T cell activation. J Virol 88:6453-6469. http://dx.doi.org/10.1128/JVI.03261-13.
71. Thammawat S, Sadlon TA, Hallsworth PG, Gordon DL. 2008. Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection. J Virol 82:11767-11774. http://dx.doi.org/10.1128/JVI.01208-08.
72. Shi Q, Jiang J, Luo G. 2013. Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. J Virol 87:6866-6875. http://dx.doi.org/10.1128/JVI.03475-12.
73. Okamoto K, Kinoshita H, Parquet Mdel C, Raekiansyah M, Kimura D, Yui K, Islam MA, Hasebe F, Morita K. 2012. Dengue virus strain DEN2 16681 utilizes a specific glycochain of syndecan-2 proteoglycan as a receptor. J Gen Virol 93:761-770. http://dx.doi.org/10.1099/vir.0.037853-0.
74. Chirkova T, Lin S, Oomens AG, Gaston KA, Boyoglu-Barnum S, Meng J, Stobart CC, Cotton CU, Hartert TV, Moore ML, Ziady AG, Anderson LJ. 2015. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol 96:2543-2556 http://dx.doi.org/10.1099/vir.0.000218.